UK Allows Early Access To Alnylam’s Lumasiran For Ultra-Rare Disorder
Executive Summary
UK patients diagnosed with primary hyperoxaluria Type 1 can now be prescribed lumasiran, which is still being reviewed for EU-wide approval. Patients in the US, Germany and other EU countries can also get the drug under early access schemes.
You may also be interested in...
‘Gene Silencing’ Drug Oxlumo Wins English Funding After Alnylam Improves Discount
Health technology assessment institute NICE has reversed its provisional rejection of Oxlumo for treating the rare disease, primary hyperoxaluria type 1.
Alnylam’s Full Lumasiran Dataset Seen As Confirming Approvability
Building on data first reported last December, lumasiran appears on pace for approval by the December 2020 action date, but Dicerna still may show its drug is best-in-class.
EU Review Gets Under Way For Lumasiran And Lonafarnib
The European Medicines Agency produces a monthly list of the marketing authorizations that are under review at the agency. The latest list contains just two new entries.